Compugen to Participate in a Fireside Chat at the 2025 Leerink Partners Global Healthcare Conference

Rhea-AI Summary

Compugen (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company specializing in computational target discovery, has announced its upcoming participation in the Leerink Partners Global Healthcare Conference. The company will engage in a fireside chat scheduled for March 11, 2025, at 8:00 AM ET in Miami Beach, Florida.

Investors and interested parties can access a live webcast of the presentation through the events page in the Investor Relations section of Compugen's website (www.cgen.com). A replay option will be made available after the live event concludes.

News Market Reaction

-5.73%

1 alert

-5.73% News Effect

On the day this news was published, CGEN declined 5.73%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

HOLON, ISRAEL  , March 3, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will participate in a fireside chat at the Leerink Partners Global Healthcare Conference, Miami Beach, Florida, on Tuesday, March 11, 2025 at 8:00 AM ET.

A live webcast of the presentation will be available on the events page of the Investor Relations section of Compugen's website at www.cgen.com. A replay will be available following the live event.

About Compugen

Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery platform (Unigen^™) to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. GS-0321 (previously COM503), a potential first-in-class, high affinity anti-IL-18 binding protein antibody, which is in Phase 1 development is licensed to Gilead. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of research programs aiming to enhance anti-cancer immunity. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.

Company contact:

Yvonne Naughton, Ph.D.
Head of Investor Relations and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071  

 

View original content:https://www.prnewswire.com/news-releases/compugen-to-participate-in-a-fireside-chat-at-the-2025-leerink-partners-global-healthcare-conference-302389891.html

SOURCE Compugen Ltd.

FAQ

When is Compugen's (CGEN) presentation at the 2025 Leerink Partners Healthcare Conference?

Compugen's fireside chat is scheduled for Tuesday, March 11, 2025, at 8:00 AM ET in Miami Beach, Florida.

How can investors watch Compugen's (CGEN) Leerink Partners Conference presentation?

Investors can watch the live webcast on Compugen's website (www.cgen.com) in the Investor Relations section's events page, with a replay available afterward.

What type of presentation will Compugen (CGEN) deliver at the 2025 Leerink Conference?

Compugen will participate in a fireside chat format presentation at the conference.

Where will the 2025 Leerink Partners Global Healthcare Conference featuring Compugen (CGEN) be held?

The conference will be held in Miami Beach, Florida.